Dr. Grothey on FDA Approval of Pembrolizumab in MSI-High CRC

Axel Grothey, MD, medical oncologist at Mayo Clinic, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with microsatellite instability-high colorectal cancer (CRC).

Axel Grothey, MD, medical oncologist at Mayo Clinic, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with microsatellite instability-high colorectal cancer (CRC).

Related Content:

OncLive TVColorectal CancerGastrointestinal CancerImmuno-Oncology
Dr Elder on the Initial Safety Profile of IGV-001 in Newly Diagnosed Glioblastoma
Dr Lukas on Survival Outcomes With Eflornithine in IDH-Mutant Anaplastic Astrocytoma
Dr Pant on the Importance of Targeted Therapy and Mutation Testing in Pancreatic Cancer